We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Levamisole Treatment Enhances Protective Antibody Response to Hepatitis B Vaccination in Hemodialysis Patients.
- Authors
Kayataş, Mansur
- Abstract
Hemodialysis shows a high risk for hepatitis B infection, and hepatitis B virus (HBV) vaccination has now become a routine procedure. Unfortunately, 40% to 50% of hemodialysis patients do not have adequate protective antibodies against the HBV vaccination which is thought to be due to depressed cell mediated immunity. Levamisole has been reported to stimulate depressed T-cell activity and enhance B lymphocyte function and restore delayed hypersensitivity reactions in immune-depressed patients. We studied the effects of levamisole, an immunomodulatory agent, on the protective antibody response of hemodialysis patients to the HBV vaccination. Our hemodialysis patients with negative anti-HBs antibody routinely received 40 μg doses of recombinant HBV vaccine intramuscularly at 0, 1, and 6 months, and we followed serum anti-HBs levels. Patients with a serum antibody level of >10 mIU/ml were considered as responders. Study groups were classified as follows. Group 1 was comprised of 96 chronic hemodialysis patients with negative anti-HBs and HBV core antibody (52 male, 44 female, mean age of 45 ± 15 years and mean hemodialysis duration of 46 ± 40 months) who received HBV vaccination; 55 patients (57%) were found to be responders. Group 2 was comprised of 19 randomly selected patients who had never received hepatitis B vaccine (13 male, 6 female, mean age of 42 ± 14 years, mean duration of hemodialysis 31 ± 27 months) and who were started on an HBV vaccination protocol with levamisole per os 80 mg after each hemodialysis session for 4 months and followed up on serum anti-HBs levels. Seventeen of the patients completed this levamisole treatment. Fourteen of the 17 patients had the levels of the protective serum antibody indicating a higher response rate when compared with patients who did not receive levamisole (82% versus 57%, respectively, p < 0.05). Group 3 was comprised of 19 patients randomly selected from persons who did not respond to...
- Subjects
LEVAMISOLE; HEPATITIS B vaccines; HEMODIALYSIS; IMMUNOGLOBULINS; DRUG efficacy
- Publication
Artificial Organs, 2002, Vol 26, Issue 6, p492
- ISSN
0160-564X
- Publication type
Article
- DOI
10.1046/j.1525-1594.2002.06928.x